US DHHS 20 chronic conditions | Eligible participants for follow-up (n=40 978) | All consented (n=56 862) | ||
Prevalent cases (%) | Incident case (%*) | Prevalent cases (%) | Incident case (%*) | |
Hypertension | 17 976 (44%) | 2034 (12%) | 20 876 (37%) | 2835 (11%) |
Congestive heart failure | 1394 (3%) | 1121 (4%) | 1592 (3%) | 1259 (4%) |
Coronary artery disease | 7388 (18%) | 1373 (6%) | 8492 (15%) | 1742 (5%) |
Cardiac arrhythmias | 13 508 (33%) | 2158 (10%) | 15 349 (27%) | 2762 (9%) |
Hyperlipidaemia | 21 817 (53%) | 1773 (12%) | 25 038 (44%) | 2596 (11%) |
Stroke | 2689 (7%) | 975 (4%) | 2969 (5%) | 1116 (3%) |
Arthritis | 17 944 (44%) | 2861 (16%) | 21 173 (37%) | 3847 (14%) |
Asthma | 3874 (9%) | 489 (2%) | 4331 (8%) | 637 (2%) |
Autism | 3 (<1%) | 6 (<1%) | 3 (<1%) | 6 (<1%) |
Cancer (selected†) | 13 648 (33%) | 2681 (13%) | 15 946 (28%) | 3379 (12%) |
Chronic kidney disease | 3604 (9%) | 2094 (8%) | 4153 (7%) | 2413 (7%) |
Chronic obstructive pulmonary disease | 3600 (9%) | 728 (3%) | 3932 (7%) | 897 (2%) |
Dementia | 714 (2%) | 813 (3%) | 893 (2%) | 906 (3%) |
Depression | 7368 (18%) | 1452 (6%) | 8040 (14%) | 1804 (5%) |
Diabetes | 11 779 (29%) | 2473 (11%) | 13 351 (23%) | 3051 (9%) |
Hepatitis | 574 (1%) | 126 (<1%) | 706 (1%) | 174 (<1%) |
HIV | 27 (<1%) | 3 (<1%) | 35 (<1%) | 8 (<1%) |
Osteoporosis | 4063 (10%) | 926 (3%) | 4405 (8%) | 1102 (3%) |
Schizophrenia | 153 (<1%) | 116 (<1%) | 168 (<1%) | 127 (<1%) |
Substance Abuse | 1305 (3%) | 662 (3%) | 1461 (3%) | 752 (2%) |
*Cumulative incidence was calculated based on the Kaplan-Meier (KM) method, which is a sum of the KM estimate of incidence of a given condition at a specified time point over time. The KM estimate at a specified time point is the number of participants having a given condition at that time, divided by the number of patients at risk (alive, disease-free and not lost to follow-up), multiplied by the probability of disease-free survival just prior to that time. Note that this estimate cannot be calculated as a simple proportion of the number of participants with a given condition, divided by the number of participants at risk at the biobank entry.
†Cancer category includes breast, colorectal, lung and prostate cancers.
US DHHS, United States Department of Health and Human Services.